Can Cui

Can Cui PhD, JD

Listen to pronunciation of my name
Can Cui PhD, JD
San Francisco
+1 415 733 6081

Dr. Can Cui is a partner in Goodwin’s Life Sciences group and a co-leader of the firm’s Life Sciences practice in Asia. His practice focuses on technology transactions and investment in the life sciences industry, especially those transactions related to China, including cross-border technology licensing and acquisition, collaboration and strategic partnership, joint venture (JV), and other forms of investment.

Dr. Cui has extensive experience representing both licensors and licensees in US-China life sciences licensing transactions. In private equity and venture capital transactions, he regularly represents institutional and individual investors, established life sciences companies and startups in intellectual property (IP) due diligence and the negotiation and drafting of related investment documentation. He also advises clients on IP aspects of mergers and acquisitions.

Dr. Cui has deep knowledge of China’s increasingly complex regulatory landscape, including not only the IP laws, but also laws and regulations governing cross-border transactions, such as technology import and export regulations, regulations of human genetic resources, and data privacy laws and regulations. He also has rich experiences in corporate matters, patent prosecution and IP dispute resolution, which, together with his scientific background, make him a go-to person for advice in various legal matters life sciences companies may have.

In addition to his legal services to the life sciences industry, Dr. Cui is also an active participant in a wide variety of pro bono matters.


Dr. Cui has advised the following companies in the following transactions and matters:

  • A start-up focused on the discovery and development of transformative therapies for the unmet medical needs of cancer patients: IP, licensing and corporate matters
  • A biopharmaceutical company focused on discovering and developing novel therapies that disrupt the cancer treatment landscape: China collaboration
  • 3E Bioventures Capital: 200 million RMB preB+ investment in Biosion Inc.
  • A company developing novel therapeutics based on gene editing, RNA editing, and delivery technology: IP and technology transactions
  • Acelyrin, Inc.: partnership agreement with Affibody AB to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A, for multiple autoimmune diseases
  • ACROBiosystems Inc.: various licensing, collaboration, sales, distribution, consulting and investment transactions, and IP matters*
  • A biotech venture capital positioned to rapidly translate scientific discoveries into innovative new medicines: China licensing matters
  • A publicly traded, global, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies: various collaboration, licensing, and services transactions, and employee IP matters*
  • A clinical stage biotechnology company advancing novel therapies for people with rare cardiopulmonary disease: clinical trials in China
  • A biopharmaceutical company focused on advancing gene therapies of short-form human factor H to restore complement regulation in dry age-related macular degeneration, atypical hemolytic uremic syndrome, and other disorders characterized by complement dysregulation: various licensing transactions
  • AfaSci, Inc.: IP, licensing and financing matters
  • A late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in ophthalmology, neurology and psychiatric disorders for patients in Greater China and around the world: patent matters
  • A company discovering and developing potent and highly differentiated human antibody therapeutics to improve the lives of patients with serious diseases: trademark matters
  • A biopharmaceutical company creating cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors: various licensing transactions and China collaboration
  • An immunotherapeutics company focused on the development of prescription therapeutics for the treatment of food allergy: various confidentiality agreements
  • A medical device company dedicated to ending obesity: China collaboration
  • A contract clinical research company with clinics in both the US and Canada: IP licensing in China and Korea
  • An international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies: patent portfolio management and various licensing transactions
  • A clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases: university licensing
  • A biotechnology company developing antibody drug conjugates: China licensing dispute resolution
  • A clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer: licensing dispute resolution
  • ARTBIO, Inc.: China licensing and various development, manufacture and logistics agreements, including those with Eckert & Ziegler Strahlen- und Medizintechnik AG, SpectronRx and PharmaLogic Holdings Corp.
  • A world leader in executing complex cell edits: various licensing transactions
  • A company devoted to bringing life-changing therapies to patients and families impacted by allergic and immunological diseases: China licensing matters
  • A leading biotech venture capital firm: licensing and services agreements of its portfolio companies
  • An orthopedics company committed to improving the experience of both patients and surgeons through innovative technologies: patent prosecution
  • Base Therapeutics: various licensing transactions, including university licensing and out-licensing of its proprietary base editing technology to a leading international biopharmaceutical company
  • A global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide: various technology transactions
  • The only biotech company in China with publicly declared focus to develop Treg immune therapy: patent matters
  • A biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases: China collaboration
  • A women-owned, science-led, and parent-centered infant nutrition company based in Durham, NC: China patent matters
  • The world’s largest publisher of investment research: China operations
  • A biomedical company working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives: China collaboration
  • CANbridge Pharmaceuticals: strategic collaboration with LogicBio Therapeutics
  • A developer of innovative diagnostics and devices to address unmet medical needs: services agreement
  • A biopharmaceutical company focused on protease therapeutics to address unmet medical needs in disorders of the coagulation systems: China collaboration
  • An innovative drug research and development company that focuses on the field of cellular immunotherapy: various licensing matters
  • A global leading biopharmaceutical company committed to translating revolutionary discoveries into pioneering medicines and medical devices for terminating cancer lethality, saving cancer patients’ lives, and improving life quality of patients worldwide: China strategies
  • A biotech company based in Menlo Park, California that focuses on the discovery and development of transformational therapeutics to combat life-threatening diseases, especially cancer: various IP matters
  • A genomic medicine company pioneering single-dose epigenetic editing therapeutics: China strategies
  • A developer of novel, coordinated immunotherapy solutions for patients: various licensing transactions
  • A developer of custom diagnostic solutions for over 25 years ranging from complex mass screening for blood banks to individual point-of-care testing with a focus on large-scale, global diagnostic needs including antibody, molecular, and antigen tests in traditional and non-traditional settings: China supply matters
  • A regenerative medicine company utilizing naturally occurring extracellular matrix based signaling molecules to treat unmet medical needs: China supply matters
  • A clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases: China collaboration
  • Eluminex Biosciences: various licensing and collaboration transactions, including:
    • global exclusive license agreement with FibroGen, Inc. on biosynthetic cornea and other recombinant human collagen products
    • acquisition of Zuretinol assets from Retinagenix Holdings
  • A leader in OLED microdisplay technology for the next generation of computing and imaging devices: China distribution matters
  • A developer of novel fully integrated power management solutions: Taiwan employment matters
  • A discovery research company developing revolutionary treatments for patients with genetic disorders: general corporate, asset transfer, financing, and licensing and services agreements
  • EQRx: China licensing and collaboration matters
  • A clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system: various licensing, collaboration, and clinical services transactions, and China IP, JV and regulatory matters*
  • Evive Biotechnology (Shanghai) Ltd.: various licensing and collaboration transactions, including with the Memorial Sloan-Kettering Cancer Center, and patent applications
  • A developer of EV charging software and hardware for forward-thinking companies around the world: development services agreement
  • Exicure: exclusive collaboration with Ipsen on treatment for rare neurodegenerative disorders
  • A global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies: China strategies
  • An oral irrigator manufacturer from China: patent prosecution
  • One of the most established independent private equity firms in Asia: IP due diligence matters
  • A consumer health and wellness products platform focused on better-for-you consumer health & personal care brands and products: China patent matters
  • A biotech company that drives drug discovery on with AI: IP matters
  • A medical research company to improve reproductive health care: China supply matters
  • A biotechnology company focused on the development of the next-generation of Chimeric Antigen Receptor T-cell immunotherapy for precision cancer treatment: patent prosecution
  • A biotechnology company developing innovative gene therapies and cell therapies that are affordable and therapeutically effective: various patent and licensing matters
  • GenScript Biotech Corporation and its clinical-stage oncology biotech subsidiary, Legend Biotech Corporation:
    • licensing transactions, including with Amgen and Noile-Immune Biotech, Inc., respectively*
    • technology services transactions*
    • strategic collaborations, including with REMD Biotherapeutics Inc.*
    • various strategic partnership transactions*
    • acquisition of CustomArray, Inc.*
    • Chinese IP law and compliance matters*
  • A clinical stage biotechnology company developing novel medicines that harness the therapeutic promise of psychedelics to revolutionize the treatment of mental illness: China and India collaborations
  • A developer of a differentiated pipeline of innovative antibody therapeutics that will potentially transform how cancers are treated: general corporate, IP, licensing and dispute resolution matters
  • HebeCell Corp: various licensing and collaboration transactions*
  • Helio Health Inc.: various licensing transactions, including with universities, and patent applications*
  • The first company in China to use induced-pluripotent stem cells and mesenchymal stem cell technology to develop a new generation of universal cell therapy products to treat clinically incurable diseases: licensing and collaboration matters
  • A global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases: licensing and collaboration matters
  • A medical device company capturing, promoting, and advancing the category of abdominal wall and pelvic floor health, using a multi-faceted, gender-specific approach: consulting agreement and various collaboration matters
  • An investment management firm managing capital on behalf of global institutions, as well as investing in public equity and private markets: various investment in life sciences companies
  • The world's leading manufacturer of external medicine: US FDA regulatory advice
  • A leading provider of innovative technology for the recovery, mobility, and improved performance of muscles and joints, and overall health for life: US and China regulatory advice
  • A biopharmaceutical company engaged in discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases: contract dispute resolution
  • A rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines: China JV
  • A clinical-stage company developing a novel class of myeloid checkpoint inhibitors: various licensing matters
  • A developer of immune cell therapy drugs for the treatment of tumors: IP and licensing matters
  • A R&D and tech consulting company based in the Greater Boston area: US regulatory advice
  • A biotechnology company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and may bring long lasting benefit to patients: license agreement with a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide
  • A company focused on the discovery, development and commercialization of oral, small molecule protease inhibitors as new treatments for diseases with significant unmet need: various joint venture, licensing and distribution transactions
  • Karuna Therapeutics: strategic collaboration with Zai Lab for development, manufacturing, and commercialization of KarXT in Greater China
  • A developer of mobile phototherapy systems: general corporate and trademark matters
  • An innovative biotechnology company intended to develop cell and gene therapy: gene editing technology licensing matters
  • Legend Capital: various venture-capital and private-equity investments, including its investment in Nuwacell Biotechnologies’ Series A financing round and in N1 Life, Inc.’s Pre-A financing round, in each case as lead investor
  • Livzon Pharmaceutical Group Inc.:
    • $33 million Series B financing of Elicio Therapeutics*
    • $47 million Series B financing of Carisma Therapeutics*
    • US regulatory advice*
  • A pioneer in a new class of treatments for neuro-visual disorders: China collaborations
  • A pharmaceutical company developing innovative products of low regulatory risks and high market potentials: financing and regulatory matters
  • Lyra Therapeutics: strategic partnership and exclusive license agreement with LianBio to develop and commercialize LYR-210 in Greater China and other Asian markets
  • A leading eClinical provider: China human genetic resources regulatory advice
  • A company that offers its customers the opportunity to invest in early-stage up to and including phase 2 biotech and pharma companies: China collaborations of its portfolio companies
  • A clinical-stage targeted oncology company: exclusive license agreement with a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immune-oncology drugs for treatment of cancer for the development, manufacturing and commercialization of an investigational tyrosine kinase inhibitor in Asia Pacific region
  • Moderna, Inc.: various license and collaboration transactions in the field of genetic medicines, including license and collaboration agreements with Metagenomi, Inc., Life Edit Therapeutics, and Generation Bio Co.
  • A venture capital and private equity investments group: China regulatory matters
  • A biotechnology company leveraging its unparalleled target and antibody discovery capability for cancer immunotherapy: collaboration with a highly specialized and innovative pharmaceutical group with annual sales revenue of more than RMB 40 billion
  • Myrobalan Therapeutics, Inc.: general corporate, employment, financing (including $24 million Series A financing), IP, and technology transactions
  • A bio-pharma company spun out from Stanford University and focusing on developing new therapeutics based on innovative drug delivery technologies to address unmet medical needs of human and companion animals: IP and technology transactions
  • A company developing small molecules to treat cancers driven by increased activity of SHP2-regulated pathways: China regulatory matters
  • NeuPharma: collaboration with Henlius in respect of a small-molecule inhibitor of BRAF V600E
  • A digital neuroscience company focused on psychedelic-inspired therapeutics aiming to discover & develop novel psychedelic-inspired therapeutics for "responder" CNS disease subpopulations: collaboration with a developer of a data and AI-driven platform capable of ingesting complex human disease data
  • A company that has nearly $10 billion in public equities, primarily in the technology sector: China IP due diligence
  • A pharmaceutical company using cutting-edge tools to make therapeutic progress against the most challenging of targets: sale of a subsidiary
  • Nuwacell Biotechnologies Co., Ltd.: IP matters
  • A startup company innovating the future of neurotoxins: China collaborations
  • A Swedish company dedicated to innovation, quality, and transparency, providing advanced products and services for protein biomarker discovery: various technology transactions and US regulatory advice
  • A strategy software provider: IP matters
  • Orna Therapeutics: collaboration with Simnova to advance Orna's next generation circular RNA technology in China
  • Palleon Pharmaceuticals: various license and collaboration transactions, including strategic collaboration with Henlius to develop bifunctional sialidase therapies
  • A biopharmaceutical company committed to solving some of the world’s most pressing public health challenges: master services agreement
  • One of the world’s largest clinical research organizations: China human genetic resources regulatory advice
  • A designer and manufacturer of lasers, laser modules and subsystems for instrumentation predominantly in biotechnology, as well as inspection, imaging and other major industries: capital market matters
  • A developer of a first-of-its-kind fermentation technology that solves the capacity problem: services agreement
  • A biotechnology company focused on precision medicine for FGFR-driven disorders: safety data exchange agreement
  • Qilu Pharmaceutical Co., Ltd.:
    • various collaboration and licensing transactions, including Greater China exclusive license and collaboration agreement with Arbutus Biopharma Corporation on Hepatitis B RNAi therapeutics
    • licensing disputes
  • RabPharma: general corporate matters and various licensing and collaboration transactions
  • A global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health: China regulatory advice
  • A biotechnology company headquartered in China’s Eye Valley: various licensing and collaboration matters
  • A healthcare company pioneering the field of integrated diagnostics: China contract dispute resolution and subsidiary China data transfer matters
  • A leading Chinese company in gene therapies based on gene editing: IP, licensing and financing matters
  • ScalmiBio: acquisition by ALX Oncology
  • Seagen: regional strategic collaboration and license agreement with Zai Lab for TIVDAK®
  • A biotechnology company seeking to outsmart complex diseases with more intelligent medicines: JV matters
  • Shorelight: China collaborations
  • A medium- and long-term equity investment fund: investment matters
  • A developer of a wearable wellness device that provides advanced safety and wellness features: development, manufacturing and purchase agreement with a manufacturer of computers, telephones, notebooks, and servers
  • A leading antibody discovery service provider with a pioneering platform that can accelerate the process and capture all available data: various licensing matters
  • A provider of a single integrated cloud-based management console: China IP dispute resolution matters
  • A China-based, global-oriented R&D company focusing on innovative drugs for diseases in the field of nervous system and autoimmunity: various licensing and collaboration matters
  • A high-tech biotechnology company co-founded by overseas experts, returnee scientists and local Chinese pharmaceutical entrepreneurs: various licensing, collaboration and financing matters
  • A tax and business consulting company intended to offer international accounting and tax practices: operating agreement, consulting agreement, and California regulatory advice
  • A clinical stage biopharmaceutical company focused on optimizing and delivering intratumoral immunotherapy to patients with metastatic cancers: China collaboration
  • T-Cure Bioscience, Inc.
    • license agreement with Immunotech Biopharm Ltd*
    • clinical research agreement with Rutgers, The State University of New Jersey*
  • A biologically-targeted radiation therapy company focused on developing novel treatment to improve the lives of patients with difficult-to-treat cancers: various distribution, license, and collaboration transactions, including with South Korean and Japanese collaborators
  • A rapidly developing company primarily engaged in the production of heat sinks, fans, and related products: IP matters
  • A cutting-edge investment institution focusing on the medical and health industry: IP due diligence matters
  • A company developing a technology that combines the noninvasive diffuse reflectance spectroscopy with patented algorithms for detecting various skin properties and body health condition: various licensing transactions
  • A company active in the field of research, development, therapeutic trials, creation, production, operation, marketing, distribution of therapeutic products for the treatment of cancer: general corporate and licensing matters
  • Triastek, Inc., a global leader of 3D printing pharmaceuticals: employee and consultant IP matters and various collaboration and services transactions, including collaboration with Ely Lilly and Company
  • A clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity: China collaboration
  • A developer of unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer: China patent advice
  • uBriGene (Boston) Biosciences Inc.: transaction with Mustang Bio, Inc.
  • An industry leader in multiplexing tools for tissue biomarker analysis: various commercial agreements
  • Vaccitech: acquisition of Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
  • Vazyme Biotech Co., Ltd: IP transactions and product distribution matters*
  • Warburg Pincus Asia LLC
    • freedom-to-operate and other China IP due diligence matters*
    • $1.2 billion Series B financing of Haihe Pharmaceutical*
    • $123 million Series D financing of Abbisko Therapeutics*
  • A startup accelerator in biotech and healthcare: academic collaborations
  • A company focused on R&D of innovative mRNA drugs and adjuvants: various patent and technology transactions matters
  • A company building computer aided diagnosis algorithms and systems in clinical imaging to improve diagnostic accuracy and effectiveness: various distribution and collaboration matters
  • A clinical Positron Emission Tomography (PET) imaging service company anchored in China and specializing in Radiotracer Production through PET acquisition to evaluate, and support development of treatments for neurodegenerative disorders including Alzheimer and Parkinson disease, Oncology and other disease pathologies: China regulatory advice
  • A provider of new drug candidates through structure-based de novo drug design to accelerate drug discovery: various licensing and collaboration matters
  • A Chinese national high-tech enterprise specializing in the research and industrialization of innovative drugs: various IP and technology transactions matters
  • *Denotes experience prior to joining Goodwin

    Professional Activities

    Dr. Cui is a member of American Bar Association, New York State Bar Association, Bar Association of San Francisco, San Francisco Intellectual Property Law Association, State Bar of Texas, and The BayHelix Group, and a lifetime member of the Chinese Bioscience Association.

    Dr. Cui is a frequent guest lecturer and panelist at top universities and law schools in the United States and in China on IP protection and technology transactions in the life sciences industry. He also serves as a mentor in the Career Advisory Network program of Chinese-American Bio/Pharmaceutical Society and an advisor to startup companies on H7 BioCapital’s global venture platform.

    Professional Experience

    Prior to joining Goodwin, Dr. Cui was an associate in the IP and Technology Transactions Groups of Morrison & Foerster LLP (“MoFo”), where he was a key member of the firm’s China Life Sciences practice. During his four-year residency in the firm’s Hong Kong office, he managed, in addition to cross-border licensing and investment transactions, patent dispute matters in China on behalf of MoFo’s US clients, and gained extensive experience in IP dispute resolution in China. During his subsequent five-year residency in MoFo’s San Francisco office, he continued to represent clients in both China and the US in their cross-border technology transactions and investments, and played a leading role in those transactions in the life sciences industry.

    While working in MoFo’s Hong Kong office, Dr. Cui was an adjunct faculty member at The Chinese University of Hong Kong (CUHK). During his three-year tenure at CUHK Faculty of Law, he taught the Principles of Intellectual Property course, and established CUHK’s Chinese IP Law course.

    Prior to and while attending law school, Dr. Cui worked as a US patent agent in the Boston and New York offices of Ropes & Gray LLP, where he was a member of the Fish & Neave IP Group.

    As a graduate student at Harvard, Dr. Cui conceived, established, and maintained a major long-term collaborative project among Harvard Medical School, the University of California, San Diego, and the Chinese Academy of Sciences. His identification of a viral microRNA was featured in the “Spotlight” section of Journal of Virology as an article of significant interest selected by the editors.




    New York University School of Law

    (magna cum laude; The Order of the Coif; Weinfeld Fellow; Walter J. Derenberg Prize, NYU Law’s only Convocation Award in IP Law; NYU Journal of Law & Business: Staff Editor (2010-11); Board Member and Senior Articles Editor (2011-12))

    PhD, Biological Chemistry & Molecular Pharmacology2007

    Harvard University

    BSc, Biotechnology2000

    Peking University

    (summa cum laude; Valedictorian; Shuping Scholar; High Distinction Honor)



    • California
    • New York
    • Texas

    Recognition & Awards

    Dr. Cui has been selected for inclusion in The Legal 500 US 2022 and 2023. Dr. Cui is recognized by Berkeley Center for Law & Technology as one of the “leading practitioners in biotech and life sciences.”


    Dr. Cui’s recent publications include:

    Dr. Cui’s recent speaking engagements include:

    • “Rules of Engagement: Navigating the Medical AI Regulations,” Artificial Intelligence in Medicine Symposium 2023, November 12, 2023
    • "Select IP and Regulatory Issues in U.S.-China Cross-Border Life Sciences Transactions,” Massachusetts Institute of Technology, October 14, 2023
    • “Issues with Investing in Companies in China,” Silicon Valley Leadership Community, October 11, 2023
    • “Future Investment Trends in Healthcare AI,” the 25th Annual Conference of the Chinese Bioscience Association, September 30, 2023
    • “Select Legal and Business Issues in Life Sciences Licensing Transactions,” H7 Healthcare Accelerator 2023, September 29, 2023
    • "IP Protection and Transaction in China,” Santa Clara University, September 27, 2023
    • “Select Legal and Business Issues in Cross-Border Life Sciences Licensing Transactions,” Zhuhai Huajin Innovation Investment Co., Ltd., April 23, 2023
    • “Law Careers Panel: Corporate, IP, Dispute/Maritime, General Practice, Legal Entrepreneurship,” Peking University School of Transnational Law, April 21, 2023
    • "Recent Developments in Healthcare Investments,” JPM 2023 Goodwin + Peking University Alumni Investor Forum, January 10, 2023
    • "Recent Developments in Healthcare Investments,” M7 Accelerator Demo Day 2022, December 9, 2022
    • “Select Issues in Biomedical Intellectual Property Transactions,” Tsinghua University-Peking University Mixer, December 4, 2022
    • “Select Legal and Business Issues in Cross-Border Life Sciences Licensing Transactions,” Hanhai BioTalk, November 27, 2022
    • "Full Life-Cycle Legal Services Needs by Life Sciences Companies,” of Texas Southwestern Medical Center, November 5, 2022
    • “Investment in Life Sciences Entrepreneurship,” the 24th Annual Conference of the Chinese Bioscience Association, October 8, 2022
    • “IP Protection and Licensing in China,” Santa Clara University, October 6, 2022
    • “Licensing, Structuring, and Fundraising Strategies for Life Science Companies Entering the US Market,” Enterprise Singapore, June 28, 2022
    • “Select Legal and Business Issues in Cross-Border Life Sciences Licensing Transactions,” MyBioGate, June 8, 2022
    • “From Scientist to Partner at International BigLaw,” Chinese American Lawyers’ Forum, March 29, 2022
    • “Select Legal and Business Issues in Cross-Border Life Sciences Licensing Transactions,” inxmed, February 25, 2022
    • “Intellectual Property Legal Workshop for Startups,” University of Southern California Viterbi School of Engineering, January 21, 2021
    • “The New Patent Law in China – Significance for Life Sciences,” Berkeley Center for Law & Technology, November 17, 2020
    • “From Scientist to Technology Transactions Lawyer – Top Things to Consider in a Career Change,” Link Your Future, Peking University Northern California Alumni Association, July 26, 2020
    • “Recent Topics on IP and Life Sciences,” Berkeley Center for Law & Technology, July 9, 2020